Goldman Sachs Upgrades TG Therapeutics (TGTX) to Neutral, 'Valuation reflects Briumvi outlook'
Tweet Send to a Friend
Goldman Sachs analyst Corinne Jenkins upgraded TG Therapeutics (NASDAQ: TGTX) from Sell to Neutral with a price target of $12.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
